Clinical Trial Update: A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

View source ↗

Summary

A completed clinical trial comparing the total health care costs of apixaban versus low molecular weight heparin in patients with venous thromboembolism and can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Venous Thromboembolism

Drugs mentioned

• Apixaban (apixaban)
• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Pfizer | Conditions: Thromboembolism | Status: COMPLETED | Results posted: 2025-10-20